NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
104 trialsNCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT05512377 2026-01-21
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
Phase 2 Completed
NCT02576431 2025-11-12
NAVIGATE
Bayer
Phase 2 Completed
NCT03044587 2025-10-01
NIFE
AIO-Studien-gGmbH
Phase 2 Completed
NCT05429203 2025-09-15
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
Stanford University
Phase NA Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05253053 2025-06-12
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT03639935 2025-06-03
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT06960733 2025-05-07
Comparison Between Winged Versus Traditional Plastic Stents for Biliary Drainage
University of Leipzig
Phase NA Completed
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT05924880 2025-04-22
TopDouble
AstraZeneca
Phase 3 Completed
NCT04338685 2024-12-09
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Hoffmann-La Roche
Phase 1 Completed
NCT05712889 2024-11-15
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Phase 1 Completed
NCT03673072 2024-11-12
GAIN
Krankenhaus Nordwest
Phase 3 Completed
NCT02443324 2024-07-31
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT04677504 2024-07-03
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT04595058 2024-04-18
BAMPI
Hospital Universitari de Bellvitge
Phase NA Completed
NCT04720131 2024-01-30
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
Phase 2 Completed
NCT05074472 2024-01-29
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
ZielBio, Inc.
Phase 1/2 Completed
NCT03230318 2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2 Completed
NCT03796429 2023-11-29
A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT03531320 2023-11-24
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
InnoPharmax Inc.
Phase 1/2 Completed
NCT03260712 2023-11-03
Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03833661 2023-10-25
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono
Phase 2 Completed
NCT04722133 2023-10-11
Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy
Yonsei University
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT05190575 2023-07-27
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT01752920 2023-06-05
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Basilea Pharmaceutica
Phase 1/2 Completed
NCT02351765 2023-05-17
ABC-08
The Christie NHS Foundation Trust
Phase 1 Completed
NCT05028439 2023-02-21
RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma
First People's Hospital of Hangzhou
Phase NA Completed
NCT02784353 2022-11-17
PReHeBP
Asan Medical Center
Phase NA Completed
NCT03101566 2022-10-28
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02489422 2022-10-14
PRO-YOU
Wake Forest University Health Sciences
Phase NA Completed
NCT03524508 2022-08-24
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
Asan Medical Center
Phase 2 Completed
NCT03110328 2022-06-15
Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Samsung Medical Center
Phase 2 Completed
NCT01899976 2022-04-13
X-MAS Biliary Study With Covered Biliary Stent
Medinol Ltd.
Phase NA Completed
NCT03162510 2022-04-07
SOLAR
National Health Research Institutes, Taiwan
Phase 1 Completed
NCT03937895 2022-03-29
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
SMT bio Co., Ltd.
Phase 1/2 Completed
NCT02703714 2022-01-25
Pembrolizumab and GM-CSF in Biliary Cancer
University of California, San Francisco
Phase 2 Completed
NCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02128282 2021-10-22
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Senhwa Biosciences, Inc.
Phase 1/2 Completed
NCT03093870 2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3 Completed
NCT04656249 2021-06-04
LENABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT04642664 2021-06-03
ACABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT04801719 2021-03-17
Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis
Brno University Hospital
Phase NA Completed
NCT01938612 2021-03-12
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed